Protalix Biotherapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Protalix Biotherapeutics, Inc. on February 22, 2012. The report discloses recent corporate events including the completion of a public offering and upcoming management presentations at industry conferences.
Key Financial Metrics
The filing does not provide specific financial statements, revenue, profit, cash flow, or margin data. The only financial metric disclosed is the completion of an underwritten public offering where underwriters exercised their over-allotment option in full to purchase an additional 675,000 shares of common stock.
Material Changes
- Capital Raise: The Company completed a previously announced underwritten public offering. Underwriters exercised their full over-allotment option for 675,000 additional shares.
- Management Activity: Yossi Maimon, Vice President and Chief Financial Officer, is scheduled to present at the Citi 2012 Global Health Care Conference on February 27, 2012, and the Credit Suisse Global Healthcare One-on-One Conference on February 29, 2012.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, financial outlook, or discussion of specific risks and contingencies beyond the standard disclosure that the press releases furnished as exhibits are not deemed "filed" for purposes of Section 18 of the Exchange Act.
Key Facts for Investor Verification
- Verify the total number of shares sold and the price per share in the completed public offering and over-allotment exercise.
- Confirm the use of proceeds from the offering as detailed in the press release filed as Exhibit 99.2.
- Review the content of the press release filed as Exhibit 99.1 for details on the upcoming conference presentations.